This company listing is no longer active
Reata Pharmaceuticals (2R3) Stock Overview
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
2R3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Reata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$161.00 |
| 52 Week High | US$161.00 |
| 52 Week Low | US$22.60 |
| Beta | 1.42 |
| 1 Month Change | 3.21% |
| 3 Month Change | 81.92% |
| 1 Year Change | 582.20% |
| 3 Year Change | 103.80% |
| 5 Year Change | 146.74% |
| Change since IPO | 730.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2R3 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.6% | 3.9% | -0.9% |
| 1Y | 582.2% | 29.3% | 1.9% |
Return vs Industry: 2R3 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 2R3 exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 2R3 volatility | |
|---|---|
| 2R3 Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2R3's share price has been volatile over the past 3 months.
Volatility Over Time: 2R3's weekly volatility has decreased from 27% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 322 | J. Huff | www.reatapharma.com |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease.
Reata Pharmaceuticals, Inc. Fundamentals Summary
| 2R3 fundamental statistics | |
|---|---|
| Market cap | €6.21b |
| Earnings (TTM) | -€82.91m |
| Revenue (TTM) | €22.22m |
Is 2R3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2R3 income statement (TTM) | |
|---|---|
| Revenue | US$23.48m |
| Cost of Revenue | US$204.15m |
| Gross Profit | -US$180.67m |
| Other Expenses | -US$93.05m |
| Earnings | -US$87.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | -769.46% |
| Net Profit Margin | -373.18% |
| Debt/Equity Ratio | 83.8% |
How did 2R3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/26 23:31 |
| End of Day Share Price | 2023/09/25 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Reata Pharmaceuticals, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Dae Gon Ha | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |